High doses of busulphan are used in conditioning regimens before stem cell transplantation. Great interpatient variations in pharmacokinetics and a correlation between toxicity and high systemic exposure of busulphan have been shown in several studies. Some authors have suggested therapeutic drug monitoring and intravenous busulphan aiming to reduce the conditioningrelated toxicity. Liposomal busulphan (LBu) might be an alternative to intravenous administration of highdose busulphan in conditioning. In the present study, we investigated the pharmacokinetics of LBu in man. Seventeen consecutive patients were enrolled in the study. LBu as a single low dose (2 to 8 mg) was given to 12 patients (six adults and six children). 
Due to its physical and chemical properties, busulphan has for a long time been available only in the oral form. Pharmacokinetic studies of the drug have shown great interpatient variations due to age, circadian rhythm, underlying disease and drug-drug interaction. [6] [7] [8] Busulphan bioavailability varies six-fold in children and two-fold in adults. 9 Several studies have shown that busulphan toxicity, such as CNS toxicity and veno-occlusive disease (VOD), correlates with a high systemic exposure expressed as area under the plasma concentration-time curve (AUC). 10, 11 Therapeutic drug monitoring and a few limited sampling models have been suggested for busulphan treatment with the aim of individualizing busulphan dosage and reducing conditioning-related toxicity. 12, 13 An intravenous form of busulphan has been recommended as a solution for the problems concerning interpatient variability in bioavailability and to ensure a safer dosing regimen. Two intravenous formulations of busulphan dissolved in organic solvents, dimethylsulfoxide (DMSO) and dimethylacetamide (DMA), have been studied. [14] [15] [16] However, both solvents have their own well-documented toxicity, which has to be considered. [17] [18] [19] A lipidbased microsuspension formulation of Bu for intravenous administration was reported recently. 20 Recently, we developed a liposomal formulation of busulphan as an alternative to intravenous high dose therapy. 21, 22 Liposomes are phospholipid-based vesicles and are suitable for delivery of many drugs, regardless of their solubility, to specific sites in the body. The distribution of liposomes depends on their size, charge and composition and this makes it possible to target different organs. 23 Several drugs, such as amphotericin B, cis-platinum, methotrexate and doxorubicin, have been introduced in liposomal form for clinical use. 24, 25 Our previously reported pharmacokinetic study in animals showed that the bioavailability of liposomal busulphan (LBu) was 0.85 in rats and 0.86 in mice, compared to busulphan dissolved in DMSO and administered intravenously (Bu/DMSO). 21, 22 The distribution of LBu was higher to the bone marrow and spleen and lower to the brain, lungs and heart, compared with Bu/DMSO. The distribution to the liver was the same with both forms. The myelosuppressive effect of LBu exceeded that of orally administered busulphan. None of our studies showed any side-effects related to the liposomal formulation itself.
The present study investigated the pharmacokinetics of LBu in man. It was divided into two parts. In the first part, patients were given a single low dose of LBu and in the second part, patients were given two high doses of LBu which replaced the first and the last dose of orally administered busulphan in the conditioning regimen. Pharmacokinetics of the liposomal and oral formulations of busulphan were studied throughout the treatment.
Patients and methods

Patients
This study followed the guidelines of the Research Board of Sweden and the Ethics Committee of Karolinska Institutet. The Swedish Drug Agency approved the LBu for intravenous administration in the present study. Seventeen consecutive patients undergoing busulfan-based conditioning for stem cell transplantation at Huddinge University Hospital were enrolled. Twelve patients (six adults and six children) were given a low dose of LBu and five patients (four adults and one child) were given two high doses. Informed consent was obtained from the adult patients, from the parents of the children, and assent from the children 8 years or older. Patient characteristics are shown in Tables 1 and 2 .
Chemicals
The following materials were used: busulphan (1,4-bis[methanesulfonoxy]butane) from Wellcome Foundation, London, UK; cholesterol, L-␣-phosphatidylcholine (egg, 100 mg/ml) and 1,2-dioleolyl-sn-glycero-3-phosphate 
Preparation of liposomal busulphan
A detailed description of the preparation of LBu has been published. 21 Briefly: lipids (L-␣-phosphatidylcholine, 1,2-dioleolyl-sn-glycero-3-phosphate and cholesterol) were dissolved in chloroform, and busulphan was added. The mixture of lipids and busulphan was dried by evaporation to a thin film in a round vessel and traces of solvent were removed under a gentle stream of nitrogen. After hydration with glucose (50 mg/ml, pH 4.0), multilamellar vesicles were formed by vortexing. The suspension was extruded five times under nitrogen pressure through two stacked polycarbonate filters with a pore size of 100 nm. Low doses of LBu with volumes within 50 ml were prepared using the extruder LiposoFast 50 (Avestin, Ottawa, Canada) and large volumes were prepared using a holder with a 2 liter capacity barrel (Aka Filter, Göttingen, Germany). The concentration of busulphan was 0.19 Ϯ 0.02 mg/ml (mean Ϯ s.d.). The LBu was prepared for each patient under aseptic conditions, sterile filtered and then stored at +4°C for no more than 24 h pending use.
Administration of liposomal busulphan
In part I, the low dose of LBu was 2, 4, 6 or 8 mg. The different doses aimed to study the relation between dose and AUC. The doses were selected randomly, except for child 1. Liposomal busulphan was administered as a short intravenous infusion (20 min) on the day before starting the conditioning regimen.
In part 2, LBu was included in the conditioning regimen which consisted of 16 high doses of busulphan (1 mg/kg every 6 h) and cyclophosphamide (60 mg/kg twice) with 24 h interval between the last dose of Bu and the first dose of cyclophosphamide. Drugs known to interact with Bu were not used during the Bu treatment. LBu replaced the first and the last doses (1 and 16) of the regimen. Doses 2 to 15 were given orally. Liposomal busulphan was increased from 0.4 mg/kg to 0.9 mg/kg and administered as an intravenous infusion for 1.5 h. The different doses were used with aim of studying a relationship between a dose and AUC. Busulfan plasma concentrations were also followed after orally administered Bu and dosing was adjusted according to estimated AUCs. Due to technical problems during the preparation of the second dose of LBu for patient No. 5, the dose was lower than intended. Throughout this paper we use the terms 'the first and last doses' of LBu.
Blood sampling
Samples were collected from permanently placed central venous catheters. Two sampling schedules were used. In part I, blood samples were collected before infusion, 5 and 15 min after starting the infusion, at the end of the infusion, and at 2.5, 5, 15 and 30 min and 1, 2, 3, 4, 6, 8 and 12 h after the infusion. Blood samples in part 2 were collected before infusion, 15, 30 and 45 min after starting the infusion, at 2.5, 5, 15 and 30 min and 1, 2, 3, 4 and 6 h after stopping the infusion. The blood was centrifuged at 2000 g and the plasma was frozen at −20°C pending assay.
Busulphan assay
Busulphan concentrations were determined in plasma. Busulphan and the internal standard (1,5-bis (methanesulfonoxypentane)) were converted to 1,4-diiodobutane and 1,5-diiodopentane, respectively. They were assayed using gas chromatography with electron capture detection. 26 
Pharmacokinetics
Concentration-time curves were adjusted to the data sets via non-linear iterative least square regression analysis. The pharmacokinetic parameters were calculated using Winnonlin version 2.0 (Pharsight, Mountain View, CA, USA). Differences between the two groups were assessed using the Mann-Whitney U test and the Wilcoxon paired t-test, whenever appropriate (GraphPad Instat 3.0, San Diego, CA, USA). Results are presented as mean Ϯ s.d.
Results
Pharmacokinetics of low-dose liposomal busulphan (part 1)
All patient data were fitted to a two-compartment model. Figure 1 shows an example of a Bu plasma concentration over time curve after the low dose of LBu. The results of the pharmacokinetic analysis are shown in Table 3 . AUCs corrected for 1 mg/kg did not differ between children and adults (5491 Ϯ 912 ng·h/ml vs 5955 Ϯ 627 ng·h/ml). C max was higher in children than in adults, but this difference was not significant. Distribution half-lives (t␣) varied from 0.02 to 0.71 h. Elimination half-lives were similar in both groups, 2.53 Ϯ 0.72 h in children vs 2.73 Ϯ 0.66 h in adults (NS). Clearance was 3.12 Ϯ 0.59 ml/min/kg in children vs 2.86 Ϯ 0.30 ml/min/kg in adults (NS). The volume of distribution was 0.61 Ϯ 0.13 l/kg in children vs 0.58 Ϯ 0.21 l/kg in adults (NS).
Pharmacokinetics of high-dose liposomal busulphan (part 2)
Plasma concentrations were fitted to a two-compartment model. An example of a concentration-time curve in high dose of LBu is shown in Figure 2 . The pharmacokinetic parameters are given in Table 4 . AUC corrected for 1 mg/kg was 6167 Ϯ 1385 ng·h/ml for the first dose and 6933 Ϯ 656 ng·h/ml for the last dose of LBu. The maximal concentrations after the first and last doses were 1340 Ϯ 744 ng/ml vs 1329 Ϯ 468 ng/ml. Half-lives were 2.90 h vs 2.84 h. Clearances were 2.81 Ϯ 0.61 ml/min/kg vs 2.45 Ϯ 0.24 ml/min/kg and apparent volumes of distribution were 0.58 Ϯ 0.14 l/kg vs 0.52 Ϯ 0.17 l/kg, respectively. Distribution half-lives (t␣) varied from 0.02 to 0.92 h.
Analysis of all patients
A significant linear correlation (P Ͻ 0.001) was found between dose and area under the plasma concentration-time curve (AUC) when all patients (low and high doses included) were analyzed ( Figure 3) . No correlation was found between age and clearance, or between age and apparent volume of distribution.
Toxicity
Patient No. 3 had a mild reaction during the first high dose of LBu. The patient felt flushing of the face, ears, neck and upper chest. Symptoms disappeared when the infusion rate was reduced. This episode did not recur during the second 
Discussion
The pharmacokinetics of busulphan have been extensively studied during recent years. These studies have shown a large interpatient variation in pharmacokinetic parameters and bioavailability. [6] [7] [8] [9] 27 Serious conditioning-related toxicity has been shown to correlate with a high systemic exposure expressed as AUC. 10, 11, 28 One way to overcome this problem could be an intravenous formulation of busulphan, enabling a plasma concentration within the therapeutic window. We have developed and preclinically evaluated liposomal formulation of busulphan suitable for intravenous administration. The present study aimed to investigate the pharmacokinetics of LBu in man. The LBu was administered in a low dose or as two doses replacing the first and the last dose in a conventional busulphan conditioning regimen and pharmacokinetic parameters were studied.
All data fitted to a two-compartment model. This differs from orally administered Bu where data are described by a one-compartment model. Data of LBu in mice were described by a one-compartment model. However, data in the rat fitted a one-or two-compartment model. The difference in models between LBu administered intravenously and orally administered Bu may mirror difference in distribution of these formulations to different compartments. In the rat, organ distribution studied with radiolabelled Bu administered intravenously either as LBu or Bu dissolved in DMSO differed between these two formulations.
A low dose of LBu was administered to six children and six adults. No difference was found between them, when AUC was corrected for the dose of 1 mg/kg. In our previous study of busulphan bioavailability, busulphan dissolved in organic solvent was administered intravenously in a low dose (about 2 mg). 9 The mean AUC obtained in that study did not differ from that of a low dose of LBu, when corrected either for 1 mg/kg (5766 Ϯ 1682 ng·h/ml and 5723 Ϯ 785 ng·h/ml, respectively) or a dose of 2 mg (426 Ϯ 281 ng·h/ml and 409 Ϯ 597 ng·h/ml, respectively). Bioavailability of LBu compared to busulphan dissolved in organic solvent is almost 100%.
No significant difference in clearance was found between children and adults (3.12 Ϯ 0.59 ml/min/kg in children vs 2.86 Ϯ 0.30 ml/min/kg in adults) and no correlation between the age and clearance was found. These results differ from our previous study of busulphan bioavailability with busulphan dissolved in organic solvent and is probably due to the fact that the children in the study of Bu bioavail- ability were younger. 9, 29 A correlation between age and busulphan clearance has been reported by others. The higher clearance in children is ascribed to their enhanced ability to metabolize busulphan through glutathione conjugation during the first pass effect in gut. 9, 29 The present investigation did not aim to study the difference in pharmacokinetics of LBu in relation to age and no age selection in children was done. Busulphan clearance values in published studies vary from 2.5 to 8.4 ml/min/kg. [6] [7] [8] 10, [30] [31] [32] However, some of the reported clearance values are based on orally administered drugs and most of these studies did not consider busulphan bioavailability.
Volume of distribution was the same in children and adults. The values we found in children differed from those in other studies. 9, 29 This may be due to a difference in the age of children among these studies and/or a difference in distribution of different formulations. In rats and mice, the Bone Marrow Transplantation apparent volume of distribution was higher for LBu than in Bu/DMSO. 21, 22 The elimination half-lives did not differ between children and adults and were similar to the halflives reported by others. [6] [7] [8] [9] [10] 20, [30] [31] [32] In the second part of the study, LBu replaced the first and last doses of the conditioning regimen. We are aware that the follow-up time of 6 h after the high dose of LBu is quite short. We did not want to change the conditioning schedule for the patients undergoing investigation. The infusion time was about 1.5 h and the half-life of Bu is about 2.5 h. We expected that the interval of 6 h between the two doses would be long enough to allow estimation of the pharmacokinetic parameters with appropriate accuracy. Clearance, apparent volume of distribution and half-life did not differ from those obtained with a low dose of LBu. In a study of the pharmacokinetics of a high dose of Bu/DMSO in man, Schuler et al found lower clearance values (1.8 Ϯ 0.7 ml/min/kg) than we did for LBu in the present study. [14] [15] [16] This could be due to differences in the properties of these two formulations. Clearance of LBu was also significantly higher than that of Bu/DMSO in rats and mice. 21, 22 No significant difference in pharmacokinetic parameters was found between the various doses of LBu used in our study.
Busulphan plasma levels were monitored after the second dose of the conditioning regimen and the AUC after oral dosing was calculated according to the published formula. 12, 13 The bioavailability of orally administered busulphan was 0.75 Ϯ 0.27 as compared to LBu administered intravenously, which is in agreement with the results published by Schuler et al. [14] [15] [16] A mean concentration of Bu in our liposomal preparation was about 0.2 mg/ml and lipid content was 16 mg/ml. An adult patient of 70 kg will receive 1400 ml of LBu a day. This volume contains 22.4 g of lipids, ie 0.32 g/kg/day. The volume and amount of lipids are feasible for human therapy. The amount of lipids administered in liposomal formulations of different drugs ranges from 1.5 to 104 mg/kg/day. 33 The amount of lipids administered during parenteral nutrition is limited by 1.5 g/kg/day. The volume of Bu microsuspension was 500 ml in 1-h infusion four times a day. 20 Furthermore, the incorporation of Bu into liposomes was higher, when NaCl was used as a solvent (0.85 mg/ml). However, the stability of liposomes in NaCl was lower (about 5 days). 21, 22 Lyophilisation may help to overcome NaCl stability problems and thus the higher concentrations of LBu will be available in the formulation.
In summary, the pharmacokinetics of LBu in man are linear for low and high doses. Intravenous administration is not dependent on absorption and therefore more predictable. No significant differences in pharmacokinetic parameters were found between adults and children after the low dose of LBu. No differences in pharmacokinetic parameters were observed between the low and high dose of LBu. No signs of toxicity related to the liposomal formulation of busulphan were detected. We believe that LBu is suitable for intravenous administration in a high dose as part of conditioning prior to stem cell transplantation. The number of patients included in part 2 of the study (high dose of LBu) is small, but was a necessary step before the start of a clinical phase I trial which is currently in progress.
